Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Elekta AB (publ)
  6. News
  7. Summary
    EKTA B   SE0000163628


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Elekta : Data from 14 leading cancer centers presented at AAPM highlight global adoption of Elekta Unity MR-Linac

07/23/2021 | 01:31am EDT

Presentation of 36 abstracts underscore the potential of Elekta Unity to advance precision radiation medicine

ATLANTA, July 23, 2021 - Elekta (EKTA-B.ST) today announced the presentation of 36 abstracts demonstrating the technical capabilities and clinical utility of the Elekta Unity MR-Linac. The research described in the abstracts was conducted at 14 leading cancer centers in North America, Europe, Asia and Australia, reflecting the broad global adoption of the system. The abstracts are being reported at the 63rd Annual Meeting & Exhibition of the American Association of Physicists in Medicine (AAPM), which is being held virtually July 25-29, 2021."The Elekta Unity data presented at AAPM clearly validate the benefits of its scan, plan and treat capabilities to enable personalized radiation therapy," said Kevin Brown, Distinguished Scientist at Elekta. "These abstracts also reflect the power of the Elekta MR-Linac Consortium,  which played a critical role in developing the technology behind  the first high-field MR-Linac,  to generate robust data that drives evidence-based clinical decision making. We continue to expand the Consortium to build the collection of data from around the world and make advanced radiation medicine available to all cancer patients, regardless of where they are treated."

Mr. Brown highlighted several abstracts that exemplify the benefits that Elekta Unity can provide to patients and care centers.

Comparison of CT-Guided and MR-Guided Adaptive Radiotherapy for Intramuscular Metastasis
Intramuscular tumors are not visible on CT scans but can be imaged on MR scans. This abstract describes data from a patient with an intramuscular tumor treated with MR-guided radiation therapy (MRgRT) using Elekta Unity. MR images were captured at the start of each treatment session and used to adapt the delivered dose to the size and shape of the tumor at the time of therapy. An algorithm was also developed to simulate the changes in daily doses that would have occurred using CT-guided radiation therapy (CTgRT). Results show that the use of CTgRT to treat intramuscular tumors can result in significant under-dosing and failure to treat the entire tumor. The authors conclude that MRgRT is ideal for treating tumors that are not visible on CT.

Real-Time Motion Tracking Based On Orthogonal Cine MRI for Abdominal Tumors On 1.5T MR-Linac
A key challenge in the use of radiation therapy to treat tumors within the abdomen is the movement of these tumors and nearby organs as the patient breathes. Real- time motion tracking (RMT) has the potential to adjust for breathing-related intra-abdominal motion and enable more precise delivery of radiation to the tumor while sparing surrounding healthy tissue and organs at risk of exposure. This abstract validates a motion tracking algorithm based on MR images captured with Elekta Unity. The algorithm was qualitatively and quantitatively validated on nine sets of abdominal MR images from eight patients with pancreatic or renal tumors and showed robust performance for real-time motion tracking, even in cases with implant-induced image artefacts or a suboptimal imaging plane.

Quantitative Relaxometry for Ultra-Hypofractionated MR-Guided Radiotherapy to the Prostate and DIL: A Feasibility Study
This study shows how T1 and T2 relaxation times (known as quantitative relaxometry) can be reliably acquired on Unity. Data was acquired in eight patients with prostate cancer while being treated with an integrated boost to the dominant intra-prostatic lesion (DIL) using ultra-hypofractionated radiotherapy on Unity. Results suggest that quantitative relaxometry may have clinical utility as an imaging biomarker to assess how tumors are responding to treatment, potentially enabling changes to the treatment plan that could improve patient outcomes.

Mr. Brown also congratulates T. Bruijnen and the team of Prof. Bas Raaymakers at University Medical Center Utrecht on the designation of their abstract, Parallel Imaging Stream for Multi-Purpose Real-Time Adaptive MRI-Guided Prostate Radiotherapy, as Best in Physics (Imaging). This abstract describes the UMCU team's successful simultaneous generation of three temporally different 3D image streams. This parallel imaging stream approach is designed to improve motion detection, thus enabling more precise real-time MRgRT of prostate tumors. The team is now focusing on integrating this multiple image stream approach to facilitate start-and-stop real-time adaptive prostate radiation therapy.

To learn more about Elekta Unity, visit elekta.com/Unity.

Elekta Unity has CE mark and 510(k) clearance but is not available in all markets.

# # #

For further information, please contact:
Mattias Thorsson, Vice President, Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com  
Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,400 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.




(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about ELEKTA AB (PUBL)
09/02ELEKTA : acquires Turkish distributor to strengthen market position
09/02ELEKTA AB (OM : EKTA B) acquired Özyürek Mümessillik ve Dis Ticaret A.S.
08/31ELEKTA : Unity MR-Linac featured in 72 abstracts at European radiation oncology congress
08/31Elekta Unity MR-Linac Featured in 72 Abstracts At European Radiation Oncology Congress
08/26ELEKTA : Board announces establishment of philanthropic Elekta Foundation
08/26ELEKTA AB (PUBL) : Ex-dividend day for interim dividend
08/25GLOBAL MARKETS LIVE : Kering, Delta Air Lines, Pfizer, Moderna, Sony...
08/25ELEKTA : Report from the Annual General Meeting 2021 in Elekta
08/25Elekta AB Approves Dividend, Payable on 1 September 2021 and on 3 March 2022
08/25Elekta AB Resolves on Dividend into Two Payments, Payable on 1 September 2021 and on 3 ..
More news
Sales 2022 14 887 M 1 713 M 1 713 M
Net income 2022 1 372 M 158 M 158 M
Net Debt 2022 857 M 98,6 M 98,6 M
P/E ratio 2022 28,6x
Yield 2022 2,06%
Capitalization 38 609 M 4 437 M 4 442 M
EV / Sales 2022 2,65x
EV / Sales 2023 2,43x
Nbr of Employees 4 000
Free-Float 93,8%
Duration : Period :
Elekta AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELEKTA AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 102,60 SEK
Average target price 116,08 SEK
Spread / Average Target 13,1%
EPS Revisions
Managers and Directors
Gustaf Salford President & Chief Executive Officer
John Adebńck Chief Financial Officer & Group Treasurer
Laurent Leksell Chairman
Steven Mark Wort Chief Operating Officer
Caroline Mofors Chief Compliance & Integrity Office, Senior VP
Sector and Competitors
1st jan.Capi. (M$)
ELEKTA AB (PUBL)-8.51%4 525